Global Hepatitis C Virus Testing Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 221 pages | ID: G4090851079EN
Precision Business Insights (PBI)

Abstracts

Hepatitis C is a liver disease which is transmitted by the contact with the blood of an infected person. Hepatitis C show significant genetic variation in population worldwide, due to high rate of viral RNA mutations. HCV has six variants (HCV genotypes 1, 2, 3, 4, 5, and 6), and 15 subtypes are recorded which vary in the rate of prevalence around the globe. Different types of devices are used for the diagnosis of hepatitis C, including HCV viral load test, HCV antibody test, HCV genotype test and liver biopsy. Inexpensive, rapid, robust, and sensitive analytical devices are essential for effective, accurate diagnosis and monitoring of disease treatment.

Increase in hepatitis C virus testing Market is mainly attributed to high incidence of chronic infection with hepatitis C virus. Furthermore, unhygienic blood donation practices are the considerable cause of spread of hepatitis C virus. Hepatitis C screening test is compulsory before the organ donation, increase in organ donation globally expected to boost the testing market growth. The increase in healthcare expenditure, changing lifestyle and increase in government initiatives are some of the key factors driving the growth of global hepatitis C virus antiviral Testing Market. In addition, growing healthcare awareness about the hepatitis C virus is also fueling the growth of global hepatitis C virus testing market. However, stringent regulation for approval of hepatitis C testing is the major factor expected to hamper the hepatitis C virus testing market.

Globally, hepatitis C virus testing market is segmented based on technique, test type, end-user.

Based on technique, hepatitis C virus testing market is segmented as:

• Polymerase Chain Reaction Tests
• Immunoassays
• Others

Based on test, hepatitis C virus testing market is segmented as:

• Hepatitis C antibody
• Hepatitis C RNA quantitative test
• Hepatitis C RNA qualitative test
• Hepatitis C RIBA
• Hepatitis C genotype
• Viral load

Based on the end-user, hepatitis C virus testing market is segmented as:

• Hospitals
• Diagnostic Centres
• Blood Donation centers

When compared to hepatitis A and hepatitis B Prevalence of hepatitis C is low. According to Institute of Liver and Biliary Sciences India (ILBS) around 3% of population globally, infected with hepatitis C virus, therefore minimum R&D investments by market players to develop new and effective hepatitis C virus tests. Among the all tests, HCV antibody testing is expected to occupy more share because antibody testing is the primarily used test for HCV testing. In end user segment, diagnostic centers is expected to have major market share in HCV testing market. Application of new electrochemical immune sensor and genosensor technologies in HPV testing are expected to change conventional HPV testing practices.

Geographically, hepatitis C virus testing Market is divided into Asia-Pacific, Latin America, North America, Europe and The Middle East and Africa. Europe hepatitis C market is expected to grow at significant rates owing to incidence of hepatitis C virus diseases. According to WHO European region have 1.5% and Eastern Mediterranean has 2.3% prevalence of HCV diseases that shows significant variations in genes in population globally due to high rates of mutation of viral RNA. Asia Pacific is expected to be having lucrative market growth over the forecasting period owing to disease prevalence rates.

Some of the players in global hepatitis C virus testing Market include Abbott Laboratories (U.S.), Bio Rad Laboratories Inc. (U.S.), Qiagen (Germany), Bayer AG (Switzerland), OraSure Technologies (U.S.), Siemens Healthcare GmbH (Germany), BioGenex (U.S.), H. Hoffman-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), and Ortho Clinical Diagnostic Inc. (U.S.), among others.

In March 2017, Siemens Healthineer’s Versant HCV Genotype 2.0 line probe (LiPA) assay gained market approval from U.S. FDA for HCV testing

In October 2015, Hologic received CE‐IVD certification for its Aptima® HCV (hepatitis C virus) Quant Dx assay on the fully automated Panther® system

In May 2011, Abbott’s RealTime PCR (polymerase chain reaction) test received testing market approval from the U.S. Food and Drug Administration for measuring the viral load of hepatitis C (HCV)

In 2010, OraQuick HCV Rapid Antibody Test was approved by the U.S. FDA that became an alternative to enzyme immunoassay testing for HCV

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL HEPATITIS C VIRUS TESTING MARKET INTRODUCTION

2.1. Global Hepatitis C Virus Testing Market– Taxonomy
2.2. Global Hepatitis C Virus Testing Market–Definitions
  2.2.1. Test Type
  2.2.2. Technique

3. GLOBAL HEPATITIS C VIRUS TESTING MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Hepatitis C Virus Testing Market Dynamics – Factors Impact Analysis
3.6. Global Hepatitis C Virus Testing Market– Recent Market Introductions

4. GLOBAL HEPATITIS C VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL HEPATITIS C VIRUS TESTING MARKET FORECAST, BY TEST TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Hepatitis C Antibody Test
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Hepatitis C RNA Quantitative Test
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Hepatitis C RNA Qualitative Test
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Hepatitis C RIBA
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Hepatitis C Genotype
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Viral Load
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis

6. GLOBAL HEPATITIS C VIRUS TESTING MARKET FORECAST, BY TECHNIQUE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Polymerase Chain Reaction Tests
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Immunoassays
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Others
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL HEPATITIS C VIRUS TESTING MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospitals
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Blood Donation Centres
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Diagnostic Centers
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL HEPATITIS C VIRUS TESTING MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Hepatitis C Virus Testing Market- Opportunity Analysis Index - By Test Type, By Technique, By End User, and Region, 2017 – 2023

9. NORTH AMERICA HEPATITIS C VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.1.1. Hepatitis C Antibody Test
    9.1.1.2. Hepatitis C RNA Quantitative Test
    9.1.1.3. Hepatitis C RNA Qualitative Test
    9.1.1.4. Hepatitis C RIBA
    9.1.1.5. Hepatitis C Genotype
    9.1.1.6. Viral Load
  9.1.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Polymerase Chain Reaction Tests
    9.1.2.2. Immunoassays
    9.1.2.3. Others
  9.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Hospitals
    9.1.3.2. Diagnostic Centres
    9.1.3.3. Blood Donation Centres
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Hepatitis C Virus Testing Market- Opportunity Analysis Index - By Test Type, By Technique, By End User, and Country, 2017 – 2023
  9.1.6. North America Hepatitis C Virus Testing Market Dynamics – Trends

10. EUROPE HEPATITIS C VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.1.1. Hepatitis C Antibody Test
    10.1.1.2. Hepatitis C RNA Quantitative Test
    10.1.1.3. Hepatitis C RNA Qualitative Test
    10.1.1.4. Hepatitis C RIBA
    10.1.1.5. Hepatitis C Genotype
    10.1.1.6. Viral Load
  10.1.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Polymerase Chain Reaction Tests
    10.1.2.2. Immunoassays
    10.1.2.3. Others
  10.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Hospitals
    10.1.3.2. Diagnostic Centres
    10.1.3.3. Blood Donation Centres
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Hepatitis C Virus Testing Market- Opportunity Analysis Index - By Test Type, By Technique, By End User, and Country, 2017 – 2023
  10.1.6. Europe Hepatitis C Virus Testing Market Dynamics – Trends

11. ASIA-PACIFIC HEPATITIS C VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.1.1. Hepatitis C Antibody Test
    11.1.1.2. Hepatitis C RNA Quantitative Test
    11.1.1.3. Hepatitis C RNA Qualitative Test
    11.1.1.4. Hepatitis C RIBA
    11.1.1.5. Hepatitis C Genotype
    11.1.1.6. Viral Load
  11.1.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Polymerase Chain Reaction Tests
    11.1.2.2. Immunoassays
    11.1.2.3. Others
  11.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Hospitals
    11.1.3.2. Diagnostic Centres
    11.1.3.3. Blood Donation Centres
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Hepatitis C Virus Testing Market- Opportunity Analysis Index - By Test Type, By Technique, By End User, and Country, 2017 – 2023
  11.1.6. Asia-Pacific Hepatitis C Virus Testing Market Dynamics – Trends

12. LATIN AMERICA HEPATITIS C VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.1.1. Hepatitis C Antibody Test
    12.1.1.2. Hepatitis C RNA Quantitative Test
    12.1.1.3. Hepatitis C RNA Qualitative Test
    12.1.1.4. Hepatitis C RIBA
    12.1.1.5. Hepatitis C Genotype
    12.1.1.6. Viral Load
  12.1.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Polymerase Chain Reaction Tests
    12.1.2.2. Immunoassays
    12.1.2.3. Others
  12.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Hospitals
    12.1.3.2. Diagnostic Centres
    12.1.3.3. Blood Donation Centres
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Hepatitis C Virus Testing Market- Opportunity Analysis Index - By Test Type, By Technique, By End User, and Country, 2017 – 2023
  12.1.6. Latin America Hepatitis C Virus Testing Market Dynamics – Trends

13. MIDDLE EAST & AFRICA HEPATITIS C VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.1.1. Hepatitis C Antibody Test
    13.1.1.2. Hepatitis C RNA Quantitative Test
    13.1.1.3. Hepatitis C RNA Qualitative Test
    13.1.1.4. Hepatitis C RIBA
    13.1.1.5. Hepatitis C Genotype
    13.1.1.6. Viral Load
  13.1.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Polymerase Chain Reaction Tests
    13.1.2.2. Immunoassays
    13.1.2.3. Others
  13.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Hospitals
    13.1.3.2. Diagnostic Centres
    13.1.3.3. Blood Donation Centres
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Hepatitis C Virus Testing Market- Opportunity Analysis Index - By Test Type, By Technique, By End User, and Country, 2017 – 2023
  13.1.6. MEA Hepatitis C Virus Testing Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Abbott Laboratories (U.S.)
  14.2.2. Bio Rad Laboratories Inc. (U.S.)
  14.2.3. Qiagen (Germany)
  14.2.4. Bayer AG (Switzerland)
  14.2.5. OraSure Technologies (U.S.)
  14.2.6. Siemens Healthcare GmbH (Germany)
  14.2.7. BioGenex (U.S.)
  14.2.8. H. Hoffman-La Roche Ltd (Switzerland)
  14.2.9. Thermo Fisher Scientific Inc. (U.S.)
  14.2.10. Ortho Clinical Diagnostic Inc. (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS